| Literature DB >> 29479987 |
Asmaa M Zaazaa1, Maha S Lokman, Aziza B Shalby, Hanaa H Ahmed, Sayed A El-Toumy.
Abstract
This research work was initiated to explore the efficacy of ellagic acid in mitigation of hepatocarcinogenesis in rats. Rats were distributed into 4 groups; negative control, hepatocellular carcinoma (HCC), doxorubicin and ellagic acid. Serum alpha-fetoprotein (AFP), glypican-3 (GPC-3), signal transducer and activator of transcription 3 (STAT3) and suppressors of cytokine signaling 3 (SOCS3) levels were assayed by ELISA. Immunohistochemical examination of hepatic VEGF expression was also conducted, along with histological procedures for examination of liver tissue sections. Significant elevation in serum AFP, GPC-3 and STAT3 levels with a significant drop in SOCS3 were observed in the HCC group. In contrast, the treated groups showed significant decline in serum AFP, GPC-3 and STAT3 levels and significant increase in SOCS3. Additionally, the HCC group declared mild positive immunoreaction for VEGF in hepatocytes while treatment with doxorubicin or ellagic acid was associated with a negative immunoreaction for VEGF. These results were supported by histological examination of liver tissue. The obtained findings suggested that ellagic acid may have beneficial chemopreventive role against hepatocarcinogenesis through its apoptotic, antiangiogenic and antiproliferative activities. Creative Commons Attribution LicenseEntities:
Keywords: Hepatocellular carcinoma; N−nitrosodiethylamine; ellagic acid; doxorubicin- rats
Mesh:
Substances:
Year: 2018 PMID: 29479987 PMCID: PMC5980924 DOI: 10.22034/APJCP.2018.19.2.387
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1Chemical Structure of Ellagic Acid
Figure 2Effect of Treatment with Doxorubicin or Ellagic Acid on Serum AFP (A) and GPC-3 (B) Levels in HCC Rat Model. (a) Significant change at P>0.05 in comparison with the negative control group, (b) Significant change at P>0.05 in comparison with the HCC untreated group.
Figure 3Effect of Treatment with Doxorubicin or Ellagic Acid on Serum STAT3 (A) and SOCS3 (B) Levels in HCC Rat Model. (a) Significant change at P>0.05 in comparison with the negative control group, (b) Significant change at P>0.05 in comparison with the HCC untreated group.
Figure 4Immunohistochemical Examination of VEGF Expression in Liver Tissues of the Studied Groups. (A)Negative control, (B) HCC untreated, (C) HCC + Doxorubicin, (D) HCC + Ellagic acid
Figure 5Photomicrograph of Liver Section of (A) negative control group shows normal histological structure of central vein (cv) and surrounding hepatocytes in the parenchyma. (H and E x 10), (B) HCC untreated group shows group of dysplastic hepatocytes with prominent nucleolus. (H and E x 40), (C) HCC + Doxorubicin group shows sever congestion in portal vein. (H and E x 40), (D) HCC + Ellagic acid group shows focal area of degenerated dysplastic with prominent nucleoli hepatocytes. (H and E x 40)